复合乳酸菌辅助三联疗法治疗幽门螺杆菌感染的临床研究

Triple Therapy Plus Lactobacillus Supplement for Helicobacter Pylori Infection

目的探讨在三联抗幽门螺杆菌(H.pylori)方案基础上加用乳酸菌对H.pylori感染的临床疗效。方法选择未接受过治疗的H.pylori感染患者148例,随机分为治疗组和对照组,每组74例。2组均给予雷贝拉唑肠溶胶片、阿莫西林胶囊、克拉霉素分散片标准三联疗法治疗1周,1周后继续使用雷贝拉唑肠溶胶片治疗3周。治疗组在上述治疗基础上加用复合乳酸菌胶囊,共4周。治疗前后行快速尿素酶试验或14 C呼气试验,并记录胃肠道症状。结果治疗组和对照组H.pylori根治率分别为86.5%和73.0%,2组比较差异有统计学意义(P=0.041)。治疗后2组胃肠道症状评分分级表(GSRS)评分均明显降低(均P=0.000 1),但治疗组降低程度明显高于对照组(P=0.000 1)。结论三联抗H.pylori方案基础上加用乳酸菌可以提高H.pylori的根治率并减轻患者的症状。

Objective To investigate the clinical efficacy of triple therapy plus lactobacillus supplement for Helicobacter pylorKH. pylori) infection. Methods A total of 148 treatment-naive patients with H. pylori infection were randomly assigned into treatment group and control group,with 74 patients in each group. All patients were treated with standard triple therapy(enteric-coa_ted rabeprazole tablets, amoxicillin capsules and clarithromycin dispersible tablets) for 1 week,followed by treatment with enteric-coated rabeprazole tablets for 3 weeks. In addition, the treatment group was given lactobacillus capsules simultaneously. Rapid urease test or 14 C-urea breathtest was performed and gastrointestinal symptoms were recorded before and after treatment. ResultsThe eradication rate of H. pylori in treatment group was higher than that in control group (86. 5% vs 7 3 .0 % j P — 0. 041). Gastrointestinal Symptom Rating Scale(GSRS) score decreased after treatment in both groups(P = 0. 000 1). However,the decrease in treatment group was more obvious than that in control group(P = 0. 000 1). Conclusion Triple therapy supplemented with lactobacillus can improve eradication rate of H. pylori and relieve gastrointestinal symptoms in patients with H. pylori infection.